Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Surg Oncol ; 26(4): 1055-1062, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30617871

ABSTRACT

BACKGROUND: Isolated limb perfusion (ILP) is a safe and well-established treatment for in-transit metastases of melanoma. In case of relapse or disease progression, ILP can be repeated (re-ILP). This study aimed retrospectively to analyze a large consecutive series of re-ILP and compare clinical outcomes with first-time ILP. METHOD: Between 2001 and 2015, 290 consecutive patients underwent 380 ILPs. Of these, 90 were re-ILPs including 68 second ILPs, 16 third ILPs, 4 fourth ILPs, and two fifth ILPs. The study evaluated response (using World Health Organization [WHO] criteria), local toxicity (using the Wieberdink scale), and complications (using Clavien-Dindo). RESULTS: The results were compared between the first ILP, the second ILP, and the third to fifth ILP. The overall response rate was respectively 83%, 80% and 68%, with a complete response (CR) rate of 60%, 41%, and 59%. In the re-ILP group, the patients with a CR after the first ILP had a 65% CR rate after the second ILP compared with 8% for the patients without a CR (p = 0.001). The risk for local toxicity or complications was not increased after re-ILP. The median overall survival periods were respectively 34, 41, and 93 months (p = 0.02). CONCLUSION: As a therapeutic option, ILP can be repeated safely for in-transit metastases of melanoma, achieving similar high response rates without increasing complications or toxicity. Re-ILP is mainly indicated for patients who already had a CR after the first ILP, whereas other treatment options should be considered for primary non-responders.


Subject(s)
Antineoplastic Agents, Alkylating/adverse effects , Chemotherapy, Cancer, Regional Perfusion/adverse effects , Extremities , Melanoma/drug therapy , Melphalan/adverse effects , Neoplasm Recurrence, Local/etiology , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Disease Progression , Female , Follow-Up Studies , Humans , Male , Melanoma/pathology , Middle Aged , Prognosis , Retrospective Studies , Skin Neoplasms/secondary , Survival Rate , Young Adult
2.
G3 (Bethesda) ; 6(7): 2213-23, 2016 07 07.
Article in English | MEDLINE | ID: mdl-27207956

ABSTRACT

Skeletal atavism in Shetland ponies is a heritable disorder characterized by abnormal growth of the ulna and fibula that extend the carpal and tarsal joints, respectively. This causes abnormal skeletal structure and impaired movements, and affected foals are usually killed. In order to identify the causal mutation we subjected six confirmed Swedish cases and a DNA pool consisting of 21 control individuals to whole genome resequencing. We screened for polymorphisms where the cases and the control pool were fixed for opposite alleles and observed this signature for only 25 SNPs, most of which were scattered on genome assembly unassigned scaffolds. Read depth analysis at these loci revealed homozygosity or compound heterozygosity for two partially overlapping large deletions in the pseudoautosomal region (PAR) of chromosome X/Y in cases but not in the control pool. One of these deletions removes the entire coding region of the SHOX gene and both deletions remove parts of the CRLF2 gene located downstream of SHOX. The horse reference assembly of the PAR is highly fragmented, and in order to characterize this region we sequenced bacterial artificial chromosome (BAC) clones by single-molecule real-time (SMRT) sequencing technology. This considerably improved the assembly and enabled size estimations of the two deletions to 160-180 kb and 60-80 kb, respectively. Complete association between the presence of these deletions and disease status was verified in eight other affected horses. The result of the present study is consistent with previous studies in humans showing crucial importance of SHOX for normal skeletal development.


Subject(s)
Bone and Bones/metabolism , Chromosome Mapping , Genome , Homeodomain Proteins/genetics , Horses/genetics , Pseudoautosomal Regions/chemistry , Sequence Deletion , Animals , Base Sequence , Bone and Bones/abnormalities , Female , Genetic Loci , Heterozygote , High-Throughput Nucleotide Sequencing , Homeodomain Proteins/metabolism , Homozygote , Male , Pseudoautosomal Regions/metabolism , Receptors, Cytokine/genetics , Receptors, Cytokine/metabolism
3.
J Physiol ; 576(Pt 3): 935-46, 2006 Nov 01.
Article in English | MEDLINE | ID: mdl-16916910

ABSTRACT

Intrauterine growth restriction (IUGR) represents an important risk factor for perinatal complications and for adult disease. IUGR is associated with a down-regulation of placental amino acid transporters; however, whether these changes are primary events directly contributing to IUGR or a secondary consequence is unknown. We investigated the time course of changes in placental and fetal growth, placental nutrient transport in vivo and the expression of placental nutrient transporters in pregnant rats subjected to protein malnutrition, a model for IUGR. Pregnant rats were given either a low protein (LP) diet (n = 64) or an isocaloric control diet (n = 66) throughout pregnancy. Maternal insulin, leptin and IGF-I levels decreased, whereas maternal amino acid concentrations increased moderately in response to the LP diet. Fetal and placental weights in the LP group were unaltered compared to control diet at gestational day (GD) 15, 18 and 19 but significantly reduced at GD 21. Placental system A transport activity was reduced at GD 19 and 21 in response to a low protein diet. Placental protein expression of SNAT2 was decreased at GD 21. In conclusion, placental amino acid transport is down-regulated prior to the development of IUGR, suggesting that these placental transport changes are a cause, rather than a consequence, of IUGR. Reduced maternal levels of insulin, leptin and IGF-1 may link maternal protein malnutrition to reduced fetal growth by down-regulation of key placental amino acid transporters.


Subject(s)
Amino Acids/metabolism , Diet, Protein-Restricted , Fetal Growth Retardation/metabolism , Fetal Growth Retardation/physiopathology , Placenta/metabolism , Amino Acid Transport System A , Amino Acid Transport Systems/genetics , Amino Acid Transport Systems/metabolism , Amino Acids/genetics , Animals , Biological Transport/genetics , Biological Transport/physiology , Down-Regulation/physiology , Female , Gene Expression Regulation/physiology , Glucose/metabolism , Insulin/blood , Insulin-Like Growth Factor I/metabolism , Leptin/blood , Placenta/physiopathology , Pregnancy , Protein Kinases/genetics , Protein Kinases/metabolism , Rats , Rats, Sprague-Dawley , Signal Transduction/genetics , Signal Transduction/physiology , TOR Serine-Threonine Kinases , beta-Alanine/analogs & derivatives , beta-Alanine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...